Floatz logo

Monovalent [B.1.351] Cov2 Pres Dtm-As03

Pediatric-Onset Multiple Sclerosis (POMS)

National Institute of Allergy and Infectious Diseases (NIAID)vaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Pediatric-Onset Multiple Sclerosis (POMS) cohort.

Asset / SponsorPhaseRating
JNJ-78436735
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
MODERNA COVID-19 VACCINE RNA
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
METHOTREXATE
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
Tozinameran
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
bnt162b2
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CC

Same molecule, other indications

Monovalent [B.1.351] Cov2 Pres Dtm-As03 is also rated in:

systemic lupus erythematosusDormant
CCC
Indicative ·
53 / 100
View asset →
pemphigus vulgarisDormant
CCC
Indicative ·
53 / 100
View asset →
rheumatoid arthritisDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →